Dr. Clay Siegall created Seattle Genetics to focus on drug development practices, helping patients, research, and scientific innovation. The company’s antibody-drug conjugate, ADCETRIS, was approved by the FDA in 2011. Seattle Genetics collaborated with Takeda Pharmaceutical Company to sell ADCETRIS in over 65 countries. The company has entered strategic licenses with AbbVie, Genentech, GlaxoSmithKline, and Pfizer to generate over $350 million. 20 ADCs are being developed using Seattle Genetics’ technology. Dr. Clay Siegall has helped the company secure over $1.2 billion in public and private financing. He is currently a board member for Ultragenyx and Washington Roundtable.
In 2013, Dr. Clay Siegall won the University of Maryland’s Alumnus of the Year for Math, Computer, and Natural Sciences. In 2012, he was named Entrepreneur of the Year by Pacific Ernst & Young. He wanted to improve oncologists’ tools after his father died of cancer when he was 24. He wants cancer patients to have access to better targeted drugs, and he is happy to wake up every day to make that goal a reality. He recommends people learn as much as they can by interacting with those that have expertise in different types of fields. Collaboration with industry leaders and innovative oncology drug developers has been crucial to his company’s business strategy.
Clay Siegall is on Alder Biopharmaceuticals’ Board of Directors and Fred Hutchinson Cancer Research Center’s Board of Governors. He is a Board Member at Mirna Therapeutics. He earned his B.S. in Zoology at the University of Maryland and his Ph.D. in Genetics at George Washington University.
From 1988 to 1991, he worked at the National Cancer Institute, National Institute of Health. 1998, he co-founded Seattle Genetics, where he is currently the CEO, President, and Chairman of the Board of Directors. He holds 15 patents and has written over 70 publications.